Abstract: TH-PO317
Nurse-Assisted Home Hemodialysis with NxStage System One Portable Machine: An Experience in the Gulf Cooperation Council (GCC)
Session Information
- Home Dialysis - I
November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 802 Dialysis: Home Dialysis and Peritoneal Dialysis
Author
- Gogoi, Satarupa, HHD Home Healthcare LLC, Dubai, United Arab Emirates
Background
Home hemodialysis (HHD) is a renal replacement therapy applied to treat active, autonomous, and relatively, healthy dialysis patients. NxStage System One, portable dialysis machine suitable for home setting. NAHHD is an innovative modality for patients providing freedom choice in dialysis therapy. Indications for NAHHD in the GCC is due to Limited Mobility, CVA, Fractures, Morbid Obesity, Intolerance to conventional HD, Infections, Mental Retardation, Psychiatric disorder. Here, at NAHHD treating mostly debilitated and frail patients with comorbidities at home and long term care facilities. Presenting clinical outcomes of Home Hemodialysis treatment, at HHD, service provider in the GCC.
Methods
The study includes 566 patients undergoing HHD treatment, for atleast more than 3 months and thus one year report of the health outcomes with portable HD machine at home was done. Estimated the HD adequacy and key performance indicators. The frequency and length of session, fluid volume calculated by dose calculator by NxStage, with target standardised KT/V ≥2.1.
Results
The total number of 566 patients (X) on NxStage machine at home and at long term care facility were included in the study. Study group selected based on duration i.e., (X >3 months). Female- 52.65% and Male- 47.35%. The mean average age of the patients, 69.06 ± 14.63. The average comorbidities: 6.114 ± 3.45 (Min-2, Max-16). The vascular access: AVF- 25.27%, AVG- 3.53%, PC- 70.67%, AVF/PC- 0.53%. The yearly average of the biological parameters with HD adequacy are shown in Table 1. The annual mortality rate is 18.02%, as shown in Graph 1.
Conclusion
The results as shown states efficient and remarkable health outcomes. Moreover, the mortality rate of the HHD patients as comapred to the US Renal Data System, shows better quality of therapy and retention in patients.